View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2021updated 12 Jul 2022 11:06am

Cyclo Therapeutics starts enrolment in Phase III NPC1 treatment trial

Based on regulatory preference for FDA and EMA compliance, this trial will have two primary goals.

Cyclo Therapeutics has initiated subject enrolment in the Phase III TransportNPC study of Trappsol Cyclo to treat Niemann-Pick Disease Type C1 (NPC1), a rare genetic disorder.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A formulation of hydroxypropyl beta-cyclodextrin, Trappsol Cyclo is intended for intravenous administration.

The enrolment initiation comes after Cyclo Therapeutics obtained regulatory and institutional review board (IRB) approval for the TransportNPC study.

Trial site activation is progressing, the company noted.

The randomised, double-blind, placebo-controlled, parallel-group, multi-centre Phase III TransportNPC study will analyse evaluate the safety, tolerability and efficacy of 2000mg/kg intravenous dose of Trappsol Cyclo plus standard of care (SOC).

This treatment combination will be compared to placebo plus SOC in NPC1 patients.

The trial intends to enrol a total of 93 paediatric patients aged between three and 18 years and adult participants at nearly 23 study centres in nine countries.

Based on regulatory needs, this trial will have two primary goals.

For the US and regions accepting the US Food and Drug Administration (FDA) guidance, the primary goal is the mean change from baseline to 48 weeks or 96 weeks.

A 4-Domain modified Niemann-Pick Disease Type C Severity Scale composite score (4D-NPC-SS) will be used to assess the improvement in Trappsol Cyclo and placebo arms.

For the EU and regions following European Medicines Agency (EMA) guidance, the trial’s primary goal is identical to that of the US, but improvement will be analysed by the 5D-NPC-SS composite score.

Cyclo Therapeutics acting chief medical officer Gerry Cox said: “Having met all of the primary endpoints of our Phase I and Phase I/II studies showing favourable safety and promising trends in efficacy with Trappsol Cyclo, we believe that Cyclo Therapeutics is well-positioned to address the systemic and neurologic manifestations of NPC, and ultimately, provide hope to people living with NPC and their families.”

The top-line interim analysis data from the trial is set to be reported in the first half of 2023.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena